SEC Filing Summary: Xcyte Therapies, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Xcyte Therapies, Inc. on August 12, 2004. The report serves to announce the company's financial results for the second quarter ended June 30, 2004. The filing incorporates a press release dated August 12, 2004, as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the referenced press release (Exhibit 99.1), which is not included in the provided text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the main body text. Investors must refer to the attached press release for comparative financial analysis.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information, including the attached exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into any filing under the Securities Act of 1933, except as expressly set forth by specific reference. No specific guidance, outlook, or risk factors are detailed in the provided text.
Key Facts for Investor Verification
- Verify the specific financial results for the quarter ended June 30, 2004, by reviewing the press release attached as Exhibit 99.1.
- Confirm the legal status of the information, noting the disclaimer regarding Section 18 liability and incorporation by reference.
- Identify the Principal Financial Officer as Kathi L. Cordova, who signed the report on behalf of the registrant.